One PBM to run Medicaid drug benefits

Summary#

A-5669 would supplement New Jersey’s Medicaid law with rules for a single pharmacy benefits manager (PBM) to administer Medicaid prescription-drug benefits. It requires the Department of Human Services (DHS) to choose and contract with that manager by January 1, 2030, and requires Medicaid managed care organizations to use it. The bill’s stated goal is to manage drug payments and rebates and, where practicable, maximize state savings.

  • DHS must run the selection process and contract with one administrator for all Medicaid pharmacy benefits, including benefits delivered through managed care organizations.
  • The contract must require the PBM to disclose payments, rebates, fees, and other financial benefits, and pass those benefits to the State. The PBM may receive a PBM fee.
  • The contract must prohibit spread pricing (charging the payer more than the pharmacy is paid) and certain fees, pharmacy requirements, and income from audits.
  • DHS must set pharmacy reimbursement methods and dispensing fees by regulation. The bill specifies drug-cost benchmarks and requires a professional dispensing fee in the reimbursement calculation.
  • DHS must review pharmacy-related contracts and changes, and conduct annual audits; audit results must be posted online.

What it means for you#

  • Medicaid recipients: One PBM would administer pharmacy benefits statewide. It could not require you to use a particular pharmacy, mail-order pharmacy, or a specialty pharmacy owned by or associated with the PBM. The bill does not itself specify changes to Medicaid eligibility or which drugs are covered.
  • Pharmacies and pharmacists: The PBM must follow DHS reimbursement rules and cannot pay less than the applicable dispensing fee when that fee is included in the State Medicaid plan and approved federally. DHS approval is required before pharmacy-related contracts or changes take effect.
  • Managed care organizations: They must contract with and use the State PBM for all Medicaid pharmacy benefits they provide. They must disclose related spending if DHS requests it.
  • PBM applicants: Applicants must disclose specified conflicts, ownership links, and manufacturer arrangements. An applicant is disqualified for specified ownership ties to a Medicaid managed care organization or licensed pharmacy, or manufacturer arrangements that create incentives for drug decisions.
  • Current-law comparison: The bill supplements New Jersey’s Medicaid law, but the existing law was not supplied, so the current division of pharmacy-benefit duties could not be verified.

Money#

No cost estimate is included in the available material.

  • DHS must supply staff and resources to run procurement, review contracts, set rules, and conduct annual audits; the bill gives no cost or staffing estimate.
  • The PBM must pay for its own annual independent audit of internal controls.
  • The bill requires the PBM to pass rebates and other financial benefits to the State, but does not estimate the amount.
  • The reimbursement method is meant, where practicable, to maximize state savings; the bill does not guarantee savings or estimate them. DHS must seek federal approvals or waivers as needed, but federal funding is not guaranteed by the text.

What is unclear#

  • The bill leaves eligibility criteria to DHS regulations. It does not set out the full selection method or how bids will be compared.
  • It does not define the PBM fee or set its amount. It also does not explain how the State will calculate or check all indirect financial benefits.
  • The bill does not explain how current pharmacy-benefit contracts would transition, or how the new arrangement would interact with existing programs and contracts.
  • It sets an RFP deadline and an effective date of January 1, 2030, but does not give a full schedule for selecting the PBM and completing implementation.
  • It does not estimate the cost of the reimbursement rules or explain how disputes, complaints, or appeals would be handled.

Case for#

  • A single administrator could give DHS direct oversight of pharmacy benefits across both Medicaid fee-for-service and managed care arrangements.
  • Requiring full disclosure and pass-through of rebates and other financial benefits could make payments more transparent and leave less room for a PBM to retain undisclosed value.
  • Banning spread pricing and PBM income from audits could reduce financial incentives that do not align with the State’s interests.
  • Annual audits and public posting of DHS audit results could help reveal whether the contract is being followed.
  • Reimbursement based on drug acquisition costs plus a dispensing fee could make pharmacy payments more explicit.

Case against#

  • One administrator would handle all Medicaid pharmacy benefits. The bill does not set performance targets or explain what happens if the arrangement fails to meet them.
  • Key details—including eligibility, reimbursement rules, and the PBM fee—are left to later regulations or the contract, so the bill itself does not show the full financial design.
  • The bill seeks savings but does not guarantee them or show that the required rules will lower total costs.
  • A possible trade-off is that requiring extensive disclosures, audits, and contract approvals could add administrative work for DHS, the PBM, managed care organizations, and pharmacies; the bill does not estimate that burden.